13031
ARDS has been associated with the administration of other monoclonal antibodies , such as infliximab , gemtuzumab ozogamicin , and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines .
 adverse effect: ARDS, gemtuzumab ozogamicin; adverse effect: ARDS, infliximab; adverse effect: ARDS, OKT3
Given options, please tell me the relationships of all the listed entity pairs.Output format is "relation1: word1, word2; relation2: word3, word4". 
Option: adverse effect 
Text: {0} 
 Entity Pairs:  ARDS, gemtuzumab ozogamicin; ARDS, infliximab; ARDS, OKT3 
Answer:
 adverse effect: ARDS, gemtuzumab ozogamicin; adverse effect: ARDS, infliximab; adverse effect: ARDS, OKT3